We tried to investigate the clinical impact of Ki-67 (MIB-1) expression on the oncological and survival outcomes in patients with bladder cancer (BCa) after the radical cystectomy.
INTRODUCTION
Bladder cancer (BCa) is the 9th most common malignancy and approximately 430,000 patients were diagnosed as BCa only in 2012. 1 BCa is also well-known to occur in the underdeveloped countries and to have strong association with male gender. The risk factors for the having BCa include Schistosoma haematobium infection, tobacco smoking, chemical exposures, and diabetes mellitus treated by pioglitazone.
2-4
The current gold-standard treatment is the radical cystectomy for the patients with muscle invasive BCa (MIBC) or high-risk recurrent nonmuscle invasive BCa (NMIBC). 5, 6 However there are no accurate biomarkers to predict the patients' prognosis after surgery, which is crucial for the patients' counseling and determining the treatment plan.
The expression of Ki-67 protein is known to be strictly associated with cell proliferation. 7 The Ki-67 protein is present only in the mitosis stage and absent in the resting stage. This fact Patients' clinical and pathological information were acquired from our database which is prospectively maintained. All surgical specimens were reviewed by senior pathologist who was totally unaware of clinical information about patients. The TNM staging was classified by using the 6th edition of the American Joint Committee cancer guidelines for BCa. 9 The pathologic results including immunohistochemistry were also collected prospectively but analyzed retrospectively. The postoperative follow-ups were usually performed at 3-to 6-month intervals at the initial 2 years and yearly thereafter. Recurrence of disease was defined as radiologic or pathologic evidence of local recurrence, distant metastasis, or mortalities from BCa.
MATERIALS AND METHODS
Postoperative evaluations were generally performed by 3 to 6 months intervals for the first 2 years and yearly thereafter but slightly differ between the attending clinicians. Mortality data was acquired from the official database of the Korean National
Statistical Office and also validated by reviewing our medical records. The RFS, CSS, and OS were determined from surgery date to progression, any-cause mortality, or cancer-specific mortality, respectively.
Immunohistochemical Assay
Specimens were fixed in 20% formalin and embedded in 
Statistical Analyses
The independent t-tests and chi-square tests were performed to compare the clinicopathological characteristics between the groups. Cox proportional hazard models were utilized to evaluate possible clinical associations on each survival end-points.
All of the statistical analyses were performed by using IBM SPSS Statistics ver. 19.0 (IBM Co., Armonk, NY, USA). All p-values were presented as two-sided and p＜0.05 was considered to be statistically significant.
RESULTS
The clinical and pathologic characteristics of patients were summarized in Table 1 Table 2 ).
The pathologic stage was also revealed as significant prognostic factor for recurrence free survival and OS. Moreover, the patients' age and neoadjuvant chemotherapy was showed significant results in the multivariate Cox analysis.
DISCUSSION
In this study, we observed that the high Ki-67 was significantly related with the worse survival outcomes after radical cystectomy in patients with BCa in terms of RFS and CSS.
Moreover the expression of Ki-67 was revealed to be independent predictor of worse RFS from the multivariate Cox analysis. Even though the Ki-67 expression did not show significant association with CSS and OS in the multivariate analyses, we think that the statistical insignificance of our results is due to our study's small number of cohort. Therefore we believe that the Ki-67 expression should be re-evaluated in the further prospectively organized studies with more large number of subjects.
The Ki-67 protein is not a novel biomarker and it's appearance is go back to 1980's. Gerdes et al. 10 first demonstrated the Ki-67 and initial prototype monoclonal antibody, which was Preceding the present study, there had been several studies which tried to elucidate the clinical usefulness of Ki-67 in the patients with BCa. 16 Margulis et al. 16 revealed that Ki-67 was independent risk factor for tumor recurrence and progression of disease.
Our study is limited by its retrospective design though our database was managed prospectively. We also admit the possibility of selection bias since only patients who underwent radical cystectomy were included in our study. Moreover, the indication for neoadjuvant chemotherapy was not controlled and varies according to the physicians and time periods, which may significantly impact the outcomes of our study. However, our study is the first study which tried to evaluate the clinical sig- 
CONCLUSIONS
The expression of Ki-67 was significantly associated with worse pathologic and survival outcomes in patients with localized prostate cancer. These findings may help the future clinicians to predict the PCa prognosis more exactly and to choose the optimal treatments.
